Terrance Truitt, MD
Pulmonary Disease · South Boston, VANPI 1922077254
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,355 of the $107,962 with a category attached, or 93.9%. GSK accounts for 93.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $43,233 and has fallen 97.7% since, to $1,009 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $325.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$101K
- Sunovion Pharmaceuticals Inc.$4K
- AstraZeneca$1K
- Amgen$391
- Regeneron Healthcare Solutions, Inc.$132
- Vifor Pharma, Inc.$122
- plus $564 from 18 others
What the payments were for
- Speaking & faculty fees$101,35594%
- Travel & lodging$1,2491%
- Food & beverage$5,2755%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 201 | $101,047 |
| Sunovion Pharmaceuticals Inc. | 40 | $4,226 |
| AstraZeneca | 35 | $1,480 |
| Amgen | 13 | $391 |
| Regeneron Healthcare Solutions, Inc. | 5 | $132 |
| Vifor Pharma, Inc. | 7 | $122 |
| Grifols USA, LLC | 4 | $91 |
| Novartis | 4 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Viatris Specialty LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Pfizer | 1 | $35 |
| Philips North America LLC | 2 | $35 |
| CSL Behring | 2 | $29 |
| Insmed, Inc. | 2 | $29 |
| United Therapeutics Corporation | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $16 |
| Breas Medical, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| Bayer | 1 | $14 |
| Merck | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$73,439
- LONHALA MAGNAIR$3,550
- TEZSPIRE$471
- FASENRA$368
- AIRSUPRA$125
How this compares
$107,962 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 664 | $546,194 |
| Breo ElliptaFluticasone/Vilanterol | 157 | $76,419 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $34,589 |
| Spiriva HandihalerTiotropium Bromide | 18 | $19,824 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $18,259 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 573 | $15,073 |
| Spiriva RespimatTiotropium Bromide | 17 | $14,308 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 65 | $11,157 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $9,701 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $5,829 |
| Ventolin HfaAlbuterol Sulfate | 87 | $4,873 |
| Ipratropium Bromide | 78 | $4,554 |
| Fluticasone Propionate | 154 | $1,836 |
| Montelukast Sodium | 140 | $839 |
| Azelastine Hcl | 21 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $101,047 | $657,201889 claims |
| AstraZenecaSymbicort | $1,480 | $18,25965 claims |
| Boehringer IngelheimSpiriva Respimat | $16 | $14,30817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in South Boston
- Pawanjit SarnaSouth Boston$19K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.